Epoetin beta biosimilar - CinnaGen

Drug Profile

Epoetin beta biosimilar - CinnaGen

Alternative Names: CinnaPoietin; rec Hu-EPO beta; rec Hu-erythropoietin beta

Latest Information Update: 21 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CinnaGen
  • Class Antianaemics; Colony-stimulating factors; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 01 Mar 2016 CinnaGen initiates enrolment in a phase III trial for Anaemia in Iran (SC, IV) (IRCT201601156135N6)
  • 31 Dec 2013 Launched for Anaemia in Iran (IV)
  • 31 Dec 2013 Launched for Anaemia in Iran (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top